ImClone LLC

ACTIVE

33 Imclone Dr, Branchburg, New Jersey, United Stateswww.imclone.comSubsidiary5,001–10,000 employeesEstablished: 1984-01-01

Part of Eli Lilly & Co.

Clinical Trials

80 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1984

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

50.0%

Phase 3

3.6%

Not Applicable

2.4%

Trial Status Distribution

Active, not recruiting

94.0%

Completed

4.8%

Not yet recruiting

1.2%

Clinical Trials

Trials sponsored by this organization (84)

A Phase 2 Study of a Human Anti-PDGFRa Monoclonal Antibody (IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)

Phase 1

Active, not recruiting

Mar 201272 participants

Estudio de fase II con un anticuerpo monoclonal humano anti-PDGFRα (IMC-3G3) en pacientes con tumores del estroma gastrointestinal (GIST) irresecable con o sin metástasis y previamente tratados. A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)

Phase 1

Active, not recruiting

Jun 201136 participants

A study of IMC-3G3 in patients with inoperable or outspread Tumors of the Gastrointestinal Stroma, already having been treated with standard treatments.

Active, not recruiting

May 201172 participants

A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib - REACH

Phase 1

Active, not recruiting

Apr 2011565 participants

A study of IMC-3G3 in patients with inoperable or outspread Tumors of the Gastrointestinal Stroma, already having been treated with standard treatments.

Active, not recruiting

Apr 201172 participants

A study of IMC-3G3 in patients with inoperable or outspread Tumors of the Gastrointestinal Stroma, already having been treated with standard treatments.

Phase 1

Active, not recruiting

Apr 201172 participants

A Study of Ramucirumab and Best Supportive Care versus Placebo and Best Supportive care in patients with second line treatment advanced liver cancer after treatment with Sorafenib.

Active, not recruiting

Mar 2011624 participants

A clinical trial to study the effects of IMC-1121B and best supportive care (BSC) versus Placebo and BSC in patients with metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first line care.

Phase 3

Completed

interventional

Dec 2010348 participants

Page 1 of 11

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

No news articles found

Back to Organizations